Benefit and risk information in prescription drug advertising: Review of empirical studies and marketing implications

Health Marketing Quarterly

Volumn 17, Issue 3, 2000, Pages 39-56

  Kopp, Steven W ^a   Bang, Hae Kyong ^b  

^a UNIVERSITY OF ARKANSAS   (United States)

^b VILLANOVA UNIVERSITY   (United States)

Author keywords

Benefit information in drug advertising; Consumer information processing; FDA regulations of drug advertising; Prescription drug advertising; Warning information in drug advertising

Indexed keywords

ADVERTIZING; DRUG INDUSTRY; DRUG LABELING; DRUG UTILIZATION; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; METHODOLOGY; PRESCRIPTION; REVIEW; UNITED STATES;

ADVERTISING; DRUG INDUSTRY; DRUG LABELING; DRUG UTILIZATION; HUMANS; MARKETING OF HEALTH SERVICES; PRESCRIPTIONS, DRUG; TRUTH DISCLOSURE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0033658023     PISSN: 07359683     EISSN: 15450864     Source Type: Journal    
DOI: 10.1300/J026v17n03_04     Document Type: Article

References (49)

1. Adams, D. G. (1994). FDA Regulation of Communications on Pharmaceutical Products. Seton Hall Law Review, 24, 1399-1417.
2. Avorn, J., Chen, M., & Hartley, R. (1982). Scientific versus Commercial Sources of Influence on the Prescribing Behavior of Physicians. American Journal of Medicine (July), 73, 4-8.
3. Beales, J. H. III, & MacLeod, W. C. (1995). Assessments of Pharmaceutical Advertisements: A Critical Analysis of the Criticism. Food and Drug Law Journal, 50, 415-449.
4. Bennett, A. R. & Boulding, M. E. (1993). FDA Attempts to Regulate Medical Textbooks. Medical Marketing & Media, 28(4), 28.
5. Chadduck, H. W. (1972). ‘’In Brief Summary”: Prescription Drug Advertising, 1962-1971. FDA Papers (February), 6(1), 13-25.
6. Craig, R. Stephen (1992). Women as Home Caregivers: Gender Portrayal in OTC Drug Commercials. Journal of Drug Education, 22(4), 303-312.
7. Draft Guidance for Industry: Consumer-Directed Broadcast Advertisements (1997). U.S. Department of Health and Human Services, Food and Drug Administration (July), [http://www.fda.gov/cder/guidance.htm].
8. Evans, C. E., Haynes, R. B., Birkett, N. J., Gilbert, J. R., Taylor, D. W., Sackett, D. L., Johnston, M. E., & Hewson, S. A. (1986). Does a Mailed Continuing Education Program Improve Physician Performance? Journal of the American Medical Association (January 24/31), 255(4), 501-504.
9. Green, W. (1995). Consumer-Directed Advertising of Contraceptive Drugs: The FDA, Depo-Provera, and Product Liability. Food and Drug Law Journal, 50, 553-567.
10. Howie, J. G., Jeffers, T. A., Millar, H. R., & Petrie, J. C. (1977). Prevention of adverse drug interactions. British Journal of Clinical Pharmacologics (October), 4(5), 611-614.
11. In the Matter of Direct-to-Consumer Promotion (1996). Comments of the Staff of the Bureau of Consumer Protection and the Bureau of Economics of the Federal Trade Commission, Docket No. 95N-0227 (January 11).
12. ITT Continental Baking Co., Inc., v. Federal Trade Commission (1976). 532 F. 2d 207-224.
13. Joubert, P. & Lasagna, L. L. (1975). Patient Package Inserts. I: Nature, Notions, and Needs. Clinical Pharmacology and Therapeutics, 18, 507-513.
14. Keown, C., Slovic, P., & Lichtenstein, S. (1981). Attitudes of Physicians, Pharmacists, and Laypersons Toward Seriousness and Need for Disclosure of Prescription Drug Side Effects. Health Psychology, 3, 1-11.
15. Keown, C., Slovic, P., & Lichtenstein, S. (1984). Influence of Risk Information About Side Effects on Perceived Risk of Prescription Drugs. Health Marketing Quarterly, 1, 111-123.
16. Kessler, D. A. & Pines, W. L. (1990). The Federal Regulation of Prescription Drug Advertising and Promotion. Journal of the American Medical Association (November 14), 264(18), 2409-2415.
17. Kordel v. United States (1948). 335 U.S. 345.
18. Krupka, L. R. & Vener, A. M. (1985). Prescription Drug Advertising: Trends and Implications, Social Science and Medicine, 20(3), 191-197.
19. Linn, L. S. & Davis, M. S. (1972). Physicians’ Orientation towards the Legitimacy of Drug Use and Their Preferred Source of New Drug Information. Social Science and Medicine, 6, 199-203.
20. Mehta, K. K., Sorofman, B. A., & Rowland, C. R. (1989). Prescription Drug Adver-rising Trends: A Study of Oral Hypoglycemics. Social Science & Medicine, 29(7), 853-857.
21. Miller, B. (1997). Why Consumer Rx Drug Ads Fail Creativity Test. Advertising Age (September 1), 18.
22. Moody, R. B., Pasadeos, Y., & Lewis, K. (1996). Direct-to-Consumer Prescription Drug Advertisements: Do They Follow FDA Guidelines? AEJMC Annual Convention-Advertising Division (August).
23. Morris, L. A. (1984). Prescription Drug Advertising to Consumers: Brief Summary Formats for Television and Magazine Advertisements. Springfield, Virginia: National Technical Information Service.
24. Morris, L. A., Grossman, R., Barkdoll, G. L., Gordon, E., & Soviero, C. (1984). A Survey of Patient Sources of Prescription Drug Information. American Journal of Public Health (October), 74(10), 1161-1162.
25. Morris, L. A., Brinberg, D., Klimberg, R., Rivera, C., & Millstein, L. G. (1986). Miscomprehension Rates for Prescription Drug Advertisements. Current Issues and Research in Advertising, 9(1), 93-117.
26. Morris, L. A., Ruffner, M., & Klimberg, R. (1987). Warning Disclosures for Prescription Drugs. Journal of Advertising Research (October), 25(5), 25-32.
27. Morris, L. A., Mazis, M. B., & Brinberg, D. (1989). Risk Disclosures in Televised Prescription Drug Advertising to Consumers. Journal of Public Policy & Marketing, 8, 64-80.
28. Oliver, R. L., Walbridge, R. H., & Rheinstein, P. H. (1983). A Study of Physicians’ Perception of the Advertising Judged Deceptive by the FDA. Advances in Consumer Research, 11, 224-228.
29. Parker, B. J. & Delene, L. M. (1997). Direct-to-Consumer Prescription Drug Advertising: Analysis and Implications. Proceedings of the Marketing & Public Policy Conference, Boston, Massachusetts (May 17).
30. Petroshius, S. M., Titus, P. A., & Hatch, K. J. (1995). Physician Attitudes Toward Pharmaceutical Drug Advertising.” Journal of Advertising Research (November/December), 35(6), 41-51.
31. Pink Sheet (1992a). Medical Journal Rx Drug Ad Survey Finds Four Potential FDA Violations Per Ad. (June 1), 54(22), 1-3.
32. Pink Sheet (1992b). Psychotropic Drug Ads Most Often Misleading in UCLA Advertising Study, HRG Says. Trade & Government (August 3), 54(31), 13-14.
33. Pink Sheet (1993). Telephone Rx Drug Ads: Side Effect Information Must Be ‘’Integral Part.” Trade & Government Memos (August 16), 55(33), 9-10.
34. Prather, J. E. (1991). Decoding Advertising: The Role of Communication Studies in Explaining the Popularity of Minor Tranquilizers. In J. Gabe (Ed.) Understanding Tranquilizer Use (pp. 112-135). London: Tavistock/Routledge.
35. Promotion of FDA-Regulated Medical Products on the Internet (1996). Notice of Public Meeting, 61 FR 48707, (September 16).
36. Rallapalli, K. C. & Smith, M. C. (1994). OTC Drug Advertising: An Analysis of Its Informational Content. Journal of Social and Administrative Pharmacy, 11(3), 139-146.
37. Roth, M. S. (1996). Patterns in Direct-to-Consumer Prescription Drug Print Advertising and Their Public Policy Implications. Journal of Public Policy & Marketing (Spring), 15(1), 63-75.
38. Schiff, G. (1990). Persantine Advertisement: Artistic License or Misleading Implication? Journal of the American Medical Association (February 2), 263(5), 658-659.
39. Seidenburg, R. (1971). Drug Advertising and Perception of Mental Illness. Mental Hygiene (January), 55(1), 21-33.
40. Sheffet, M. J. & Kopp, S. W. (1990). Advertising Prescription Drugs to Consumers: Headache or Relief? Journal of Public Policy & Marketing, 9, 42-61.
41. Stimson, G. V. (1975). Information Contained in Drug Advertisements. British Medical Journal, 4, 508-509.
42. Stimson, G. V. (1977). Do Drug Advertisements Provide Therapeutic Information? Journal of Medical Ethics, 3, 7-13.
43. Stryer, D. & Bero, L. A. (1996). Characteristics of Materials Distributed by Drug Companies: An Evaluation of Appropriateness. Journal of General Internal Medicine (October), 11, 575-583.
44. Tucker, G. K. & Smith, M. C. (1987). Direct-to-Consumer Advertising: Effects of Different Formats of Warning Information Disclosure on Cognitive Reactions of Adults. Journal of Pharmaceutical Marketing & Management (Fall), 2(1), 27-41.
45. U.S. v. Articles of Drug Century Food Co. (1963). US District Ct., Second District, Illinois, Food & Drug Law Institute Judicial Review, 1796.
46. United States v. Fifteen Cartons…of Sekov Reducer (1942). 45 F. Supp. 52-54.
47. Vener, A. M. & Krupka, L. R. (1986). Over-the-Counter Drug Advertising in Gender Oriented Popular Magazines. Journal of Drug Education (Winter), 16(4), 367-381.
48. Wilkes, M. S., Doblin, B. H., & Shapiro, M. F. (1992). Pharmaceutical Advertisements in Leading Medical Journals: Experts Assessments. Annals of Internal Medicine (June 1), 116(11), 912-919.
49. Williams, J. R. & Hensel, P. J. (1991). Changes in Physician Sources of Pharmaceutical Information: A Review and Analysis. Journal of Health Care Marketing (September), 11(3), 46-60.